Summary
Spruce Point Capital Management LLC, a research firm known for its activist short reports, has published a detailed analysis criticizing Xylem Inc.'s acquisition of Evoqua Water Technologies Corp. The report highlights significant financial, operational, and governance issues facing Xylem post-acquisition.
Who is Xylem Inc.
Xylem Inc. is a global water technology company listed on the NYSE under the ticker XYL. It offers products and services related to water infrastructure, applied water, and measurement & control solutions, focusing on managing and enabling water usage efficiently for industrial, residential, and municipal customers worldwide. The company aims to leverage digital technologies and emerging markets for growth.
Key Points from Report
Concerns Over Acquisition Valuation and Synergies
- Xylem paid a high premium for Evoqua at approximately 22x 2023E Adj. EBITDA, described as "crazy expensive" by former executives, resulting in significant dilution (25% to Evoqua shareholders).
- Cost synergies touted at $140 million over three years hide $90 million of necessary costs to achieve them, with one former executive estimating $200 million needed.
- Revenue synergies are unquantified and likely overstated, with evidence of intercompany sales and competition overlap causing revenue dis-synergies.
Financial and Operational Challenges
- Xylem exhibits declining organic orders and backlog growth, indicating weakening demand across major segments.
- Days inventory outstanding and inventory to sales ratios are at record highs, signaling working capital and liquidity pressure.
- Evoqua's financials are opaque, with recent SEC fraud charges related to revenue recognition, an ongoing federal Department of Justice investigation, and disappointing margin performance.
- Xylem disclosed two conflicting sets of financial statements, casting doubt on the accuracy of its cash position and financial reporting.
- Xylem’s digital growth story is questioned, with digital sales reportedly dilutive to margins and integration challenges hampering scale.
Governance and Leadership Concerns
- The resignation of Xylem's Audit Chair before the Evoqua acquisition, replaced by Victoria Harker, who has a controversial history including roles during major accounting scandals (MCI/WorldCom) and recent board departures.
- Xylem’s CEO initiated a stock sale program shortly after the Evoqua deal was announced, raising questions about management's confidence.
- Changes to management's incentive plan exclude stock compensation costs, potentially misaligning incentives with shareholders.
Activ8 Finance Analysis
The Spruce Point report on Xylem’s acquisition of Evoqua raises significant red flags regarding valuation, operational performance, and governance. The concerns about accounting irregularities, unmet financial synergies, and corporate leadership instability suggest an elevated risk environment. Investors should carefully consider the complexity and uncertainty revealed around the acquisition and its integration challenges.
While the narrative promoted by management highlights growth potential through digital initiatives and synergies, the evidence points to significant execution risks. The discrepancies in financial disclosures and increased working capital stress call for a cautious examination of Xylem’s reported results and future prospects.